Jump to Navigation

In April 2005, the FDA issued an alert about the potential dangers of the painkiller Celebrex (celecoxib) in response to reports from several long-term National Institute of Health (NIH) prevention studies. The NIH studies indicated that the drug was associated with cardiovascular disorders and gastrointestinal bleeding that could lead to death. The FDA advised Pfizer, Inc., the drug maker, to include a boxed warning in the Celebrex (celecoxib) label indicating the potential for cardiovascular and gastrointestinal bleeding associated with its use. The FDA identifies other risks of taking Celebrex to including liver damage, kidney problems and fluid retention, which can lead to heart failure. The FDA had approved Celebrex in 1998 as a prescription relief for joint pain, stiffness, and swelling related to arthritis. It is also used for painful menstrual cycles and for acute pain in adults resulting from surgery or dental operations. Pfizer touts its "24 hour" effectiveness, but is now required to disclose its sometimes fatal side effects.

If you have taken Celebrex and think you have suffered any heart or gastrointestinal effects as a result, please obtain a Free Consultation by submitting our online form, or by calling 866-273-1941.

OFFICE LOCATION: 707 Grant Street, Suite 2500 | Pittsburgh, PA 15219 | Phone: 866-273-1941 | Fax: 412-281-4229 | Email Us | Get Directions